Absstract of: EP4841260A1
The present invention relates to a cartridge for the uptake and analysis of a fluid sample with respect to the presence and/or quantity of a target, comprising one or more reaction zones and one or more transport zones, which zones are designed for contacting of reagents with a sample, wherein said one or more zones comprise as reagent one or more free first interactor(s) of said target. Further envisaged is a system comprising the cartridge and a handheld device. Moreover, the present invention is directed to a method of reducing the active concentration of a target in a fluid sample as well as a use of the cartridge or system for immunological assays.
Absstract of: EP4841262A1
The present disclosure belongs to the field of biological detection, and particularly relates to a protein antigen combination for detection of Alzheimer's disease (AD) and use thereof. The specific technical solution is as follows: An antigen combination is provided, wherein the antigen combination at least simultaneously includes any two of the following proteins: DOC2A, LGALS1, KDM4D, and ADARB1. The present disclosure provides several new protein antigens and the combination thereof, which can be used for early-screening detection or diagnosis of AD, and are particularly suitable for risk assessment and prediction prior to the onset of AD. Meanwhile, the protein antigens and the combination thereof can distinguish AD from other types of dementia, and can be further prepared into related reagents or kits according to needs.
Absstract of: US20260356842A1
The present disclosure is directed to adenine analogs, methods of making adenine analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and/or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Absstract of: US20260356933A1
0000 The present invention relates to single-domain antibodies (sdAbs) binding interleukin 6 (IL6). In particular, the invention relates to sdAbs that bind IL6 within a specific range of an on-rate constant and off-rate constant. The sdAbs of the present invention can associate and dissociate with IL6 in a continuous manner. The invention further relates to nucleic acids encoding anti-IL6 sdAbs, methods for detecting IL6, methods of treatment and diagnosis making use of the anti-IL6 sdAbs, methods for monitoring IL6 levels and apparatuses comprising the anti-IL6 sdAbs.
Absstract of: WO2026236212A1
Described herein are methods and devices that deplete or reduce CD41+ and/or CD61+ Platelet Derived Extracellular Vesicles (PEVs), or fragments thereof, which improve the efficacy of therapies used for the treatment of various diseases, such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), vasculitis, Systemic Sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, a blood cell disorder, or any combination thereof. In particular, methods and devices employing extracorporeal devices that deplete CD41+ and/or CD61+ PEVs, or fragments thereof, present in a subject, are provided.
Absstract of: WO2026236730A1
The inventors discovered methods to enrich small extracellular vesicles (sEVs) for neuron-derived sEVs (NDEs). Methods, systems, and kits for enriching sEVs from NDEs are disclosed herein. The methods comprise contacting a plurality of small extracellular vesicles (sEVs) with a binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate a binding reagent-NDE complex. The NDE-specific marker may be selected from synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alpha1 (GABRA1), or a combination thereof.
Absstract of: WO2026234294A1
The present invention refers to an in vitro method for assessing and/or monitoring the degree of intestinal barrier integrity and/or permeability in a subject.
Absstract of: WO2026234039A1
Methods of identifying, predicting, staging or prognosticating a disease of the macula in a subject, comprising identifying stressed cells in an image of the retina of a subject and assessing the arrangement of the one or more labelled cell stress marker positive cells using angular plot analysis.
Absstract of: US20260357219A1
Apparatuses, systems, and methods are provided for culturing a buoyant target tissue using a sandwich construct. Embodiments include preparing a buoyant target tissue in a sandwich construct for shipment, and preparing a sandwich construct comprising live tumor tissue for evaluation of candidate therapies for treating the tumor. The buoyant target tissue may include various cell types including cancer cells and tumors.
Absstract of: US20260358351A1
A use of a new highly toxic amyloid oligomer Aβo*3F as a target for diagnosing Alzheimer's disease (AD) in the early stage and the middle-late stage and mild cognitive impairment (MCI) caused by AD. The Aβo*3F specifically binds to a antibody 3F and is present in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and patients with MCI caused by AD, and the levels show highly significant differences in CSF, blood and/or brain tissue of AD patients, MCI patients and healthy elderly persons. In addition, the Aβo*3F is an ultra-highly toxic oligomer, is the most important toxic component in an Aβ oligomer mixture, has a strong pathogenic effect, and plays a key role in the occurrence and development of AD.
Absstract of: US20260358355A1
Tools for identifying risk of and for treating vascular contributions to cognitive impairment and dementia (VCID) and stroke-induced cognitive impairment in a subject are provided and include a method and a device that involve detecting target proteins in systemic blood sample from the subject.
Absstract of: US20260358352A1
The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.
Absstract of: US20260358354A1
Methods and systems for diagnosis, detection, monitoring, and treatment of traumatic brain injury are described. The methods and systems include detection of salivary biomarkers associated with brain injury in a human subject, one application of which is to determine whether the subject has sustained a concussion or a more severe traumatic brain injury (TBI). Detection of the salivary biomarkers can also provide a basis to determine that a subject can safely return to play in an athletic event and can provide a basis to evaluate the efficacy of particular treatments. The methods and systems may be implemented, for example, by means of a kit.
Absstract of: US20260357477A1
0000 Provided herein are biopanning methods for identifying peptides that bind to one or more glial cell subtypes, and peptides identified using the methods described herein. In some embodiments, provided herein are biopanning methods for identifying peptides that bind to glial cell subtypes including surveying glial cells, active glial cells, and/or primed glial cells.
Absstract of: US20260355253A1
Several embodiments relate to methods of generating cells with therapeutic potency. Several embodiments relate to generating cells as a source of exosomes with therapeutic potency. The cells and exosomes with therapeutic potency are useful for repairing and/or regenerating damaged or diseased tissue, for example.
Absstract of: US20260358353A1
Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.
Absstract of: DE102025117473A1
Die Erfindung betrifft ein Verfahren für die Diagnose einer neurodegenerativen Krankheit eines Individuums, bei dem in-vitro in einer biologischen Probe des Individuums eine für die Diagnose der neurodegenerativen Krankheit charakteristische Expression eines Proteins mittels einer Analyse eines für die Expression des Proteins spezifischen Biomarkers bestimmt wird.Die Erfindung zeichnet sich dadurch aus, dass das Protein ausgewählt ist aus HMG-CoA Synthase, SERPINA3, Pyruvat-Carboxylase, SCP-2, Myosin light polypeptide 6 und/oder Heat shock protein 60.Die Erfindung betrifft zudem zwei pharmazeutische Erzeugnisse sowie ein Kit und eine Verwendung.
Absstract of: WO2026236202A1
Primate animal models of cardiac arrhythmias and methods of using such primate animal models for research and development and screening of therapeutics for treating cardiac arrhythmias are provided. In particular, lemurs were identified for use as animal models having different naturally occurring arrhythmias resembling human electrocardiographic (ECG) pathologies. In addition, genetically modified non-human primates and induced pluripotent stem cell-derived sinoatrial nodal pacemaker cells (iSANCs) comprising a loss-of-function mutation in an SLC41A2 gene linked to atrial arrhythmia and sinus node dysfunction and their use in screening therapeutics for treating atrial arrhythmia and sinus node dysfunction are also provided.
Absstract of: WO2026236510A1
Provided are compositions, systems, methods, and kits for genetically encoded, single-cell, spatiotemporally resolved, multiplexed recording of cellular activity in mammalian cells, including in living mammalian brain tissue. The disclosure provides self-assembling intracellular protein filaments, designated CytoTape and CytoTape-vivo, and corresponding nucleic acid constructs and recombinant viral vectors, that record one or more cellular activities and one or more user-defined temporal references as spatial distributions of detectable tags along the filament. The disclosure further provides systems and methods for brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in non-human mammalian subjects, designated GLOBE recording, including recording of immediate-early-gene transcriptional activity at single-cell resolution across multiple anatomically distinct brain regions over multi-day recording windows. The disclosure further provides applications for characterizing gene regulatory networks, transcriptional dynamics, and brain-wide cellular activity in research, drug discovery, and disease-modeling contexts.
Absstract of: EP4838226A1
0001 A method of quantifying plasmalogen includes: a measurement sample preparation step of mixing a specimen containing protein and plasmalogen with Schiff reagent, to obtain a measurement sample; a control sample preparation step of mixing the specimen with a solvent of the Schiff reagent, to obtain a control sample; a measurement step of measuring a degree of a first optical property of the measurement sample after reaction of the Schiff reagent with an aldehyde generated from a vinyl ether bond of the plasmalogen, and a degree of an optical property of the control sample; and a determination step of determining a plasmalogen concentration in the specimen by comparing a corrected degree obtained by correcting the degree of the first optical property with the degree of the optical property of the control sample, with a degree of a second optical property of a standard sample containing Schiff reagent and plasmalogen having a known concentration, the degree of the second optical property being obtained after reaction of the Schiff reagent with an aldehyde generated from a vinyl ether bond of the plasmalogen.
Absstract of: EP4837918A1
The present invention relates to a surface-functionalized optical element comprising an IR-transparent optical element, wherein at least a part of the surface of the IR-transparent optical element is surface-functionalized, wherein said surface functionalization comprises a surface attachment moiety covalently attached to the surface of the IR-transparent optical element, and wherein at least part of the surface attachment moieties is covalently attached to a spacer moiety comprising a poly(alkylene oxide), wherein at least part of the spacer moieties is covalently attached to a charge optimization moiety, wherein said charge optimization moiety comprises a functional group that is charged under conditions of use of the optical element and optionally a poly(alkylene oxide), wherein at least part of the charge optimization moiety is covalently attached to a linker moiety comprising a poly(alkylene oxide), wherein at least part of the linker moieties is covalently attached to a molecular probe. The invention further relates to a single chain variable fragment (scFv) that can be used as a molecular probe for the capture of alpha-synuclein as well as sensor elements and sensors comprising said surface-functionalized optical element and/or scFv, and methods and uses thereof.
Absstract of: MX2021010517A
The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
Absstract of: WO2025073987A1
Disclosed herein is a device and method for measuring spatial mass distribution profiles to weigh the accumulated-aggregated mass of an analyte in a crowded bioorganic material background by employing a high frequency recognition pattern. The recognition pattern allows for the Fourier filtering of mass sensitive image data for background and noise subtraction. The device and method enables the screening of a biological fluid sample for an analyte associated with proteinopathy.
Absstract of: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Nº publicación: JP2026537430A 09/11/2026
Applicant:
ザ・ジョンズ・ホプキンス・ユニバーシティ
Absstract of: WO2025090981A1
The present disclosure provides a method of evaluating a mechanism of bipolar disorder, in particular mood switch, in human-derived neurons which may include providing a mechanism of an attenuated protein interaction of CaV1.2 and BK that can cause the calcium signaling deficit, the main cellular phenotype. The present disclosure further provides a method of evaluating a composition for efficacy in treating bipolar disorder, including providing a genetically modified mouse exhibiting BK channel haploinsufficiency; administering the composition to the genetically modified non-human animal; exposing the genetically modified mouse animal to a mild stressor; and determining whether the genetically modified mouse animal experiences a behavioral switch. The present disclosure also provides a method of treating bipolar disorder in a subject in need thereof, including administering to the subject a therapeutically effective amount of a BK channel agonist.